Search Results for "Cancer Immunocore Killer May 2012"
Original Source: Revolutionary new cancer targeting technology described in Nature Medicine
(Oxford, UK, 6th May 2012) A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. The most advanced of Immunocore’s ImmTACs, a drug called IMCgp100, is already in clinical trials in the UK and US for the treatm...
Matching Channels
Immunocore’s ImmTAC technology enables the immune system to recognise and kill cancer or viral cells. T Cell Receptors naturally recognise diseased cells and Immunocore’s competitive ad...
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated...
Ovarian cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian cancer are those who have had fe...
Matching News
Immunocore announces award of £2.4m from Biomedical Catalyst Fund (News)
5 November 2012: Oxford, UK - Immunocore Limited today announced that is has been awarded a grant totalling £2.4 million from the government-backed Biomedical Catalyst fund. Immunocore ...
Immunocore & Adaptimmune: Battling Cancer
James Noble, CEO of both Immunocore and Adaptimmune joined Fintan Walton at BioTrinity to talk through the separate business models the two companies have despite having been founded with the same pla...
Immunocore announces appointment of Eva-Lotta Allan to the Board (News)
02 May 2013: Oxford, UK - Immunocore Limited, the Oxford-based biotechnology company developing novel drugs to treat cancer and viral disease, today announced the appointment of Eva-Lotta Allan ...
For US Hispanics, cancer top killer, not heart
Cancer is now the leading killer of Hispanics in the U.S. — the latest sign it's beginning to displace heart disease as the nation's top cause of death.The rest of the country may not be far behind...
Cancer-specific killer T cells created from induced pluripotent stem cells (iPSC)
Researchers in Japan report today that they have succeeded for the first time in creating cancer-specific immune system cells called killer T lymphocytes from induced pluripotent stem cells (iPS cells...
Finding On Killer Cells Opens New Avenue For Combating AIDS, Cancer And Other Diseases
A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an...
Immunocore announces appointment of Eva-Lotta Allan to the Board
New position will strengthen management team as company expands operations (Oxford, UK, 2 May 2013) Immunocore Limited, the Oxford-based biotechnology company developing novel drugs to treat ca...
Matching PubMed Articles
Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma.
Cho and coworkers show that Ewing's sarcoma cells are highly sensitive to expanded allogeneic natural killer (NK) cells, partially through a NKG2D- and DNAM-1-dependent mechanism. Using an orthotopic...
Targeting natural killer cells and natural killer T cells in cancer.
Natural killer (NK) cells and natural killer T (NKT) cells are subsets of lymphocytes that share some phenotypical and functional similarities. Both cell types can rapidly respond to the presence of t...
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization. Thr...
Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is n...
As the killer toxin produced by Williopsis saturnus WC91-2 could kill many sensitive yeast strains, including the pathogenic ones, the extracellular killer toxin in the supernatant of cell culture of...
